Therapeutic effect of San Bi Tang combined with glucosamine sulfate capsules in cold-dampness-type knee osteoarthritis

BACKGROUND Cold-dampness-type knee osteoarthritis is a common middle-aged and elderly disease,but its pathogenesis is not fully understood,and its clinical treatment has limitations.Glucosamine sulfate capsules are commonly used for treating arthritis,and San Bi Tang is a classic formula of traditional Chinese medicine(TCM)that has the effects of warming yang,dispelling dampness,relaxing muscles,and activating collaterals.This research hypothesized that the combination of modified San Bi Tang and glucosamine sulfate capsules could enhance the clinical efficacy of treating cold-dampness-type knee osteoarthritis through complementary effects.AIM To analyze the clinical efficacy of San Bi Tang combined with glucosamine sulfate capsules when treating cold-dampness-type knee osteoarthritis.METHODS A total of 110 patients with cold-dampness-type knee osteoarthritis were selected as research subjects and randomly divided into a control group and an experimental group of 55 cases each.The control group received only treatment with glucosamine sulfate capsules,while the experimental group received additional treatment with modified San Bi Tang for a duration of 5 wk.The patients’knee joint functions,liver and kidney function indicators,adverse reactions,and vital signs were evaluated and analyzed using SPSS 26.0 software.RESULTS Before treatment,the two groups’genders,ages,and scores were not significantly different,indicating comparability.Both groups’scores improved after treatment,which could indicate pain and knee joint function improvement,but the test group had better scores.The TCM-specific symptoms and the clinical efficacy of the treatment in the test group were higher.Before and after treatment,there were no abnormalities in the patients’liver and kidney function indicators.CONCLUSION The combination of modified San Bi Tang and glucosamine sulfate capsules is superior to treatment with sulfated glucosamine alone and has high safety.

Modular Combination Design of Mine Rescue Capsule Based on Load Simulation

Mine rescue capsule is a typical emergency equipment in a coal mine.It provides a safe and confined space for miners when mining disasters occurred.The length of the passenger survival cell is suitable to be adjusted with several predefined modular cells according to various numbers of passengers.Aiming at the shortage of guidance rules for the modular combination design of mine rescue capsule,the configuration situations of survival cells are experimented with static and impact load analysis in ANSYS Workbench.The length range of a single cell,the combination schemes of miner survival section,and the effectiveness proof of assembled rescue capsules were solved sequentially by simulated load analysis on constructed structural models.The modular combination rules of the survival section are developed for variant passenger number ranging from 8 to 20.It also provides a reference for the optimal selection of rescue capsules with the same capacity.The proposed modular rules are effective for the rapid configuration design for mine rescue capsule driven by the number of passengers.

Effects of Digoxin and Tongxinluo capsule combination treatment on oxidative stress, cytokines and vascular endothelial function in patients with chronic heart failure

Objective:To explore the effect of digoxin and Tongxin capsule combined therapy on oxidative stress, cytokines and vascular endothelial function in patients with chronic heart failure, and provide help for clinical treatment of patients with chronic heart failure.Methods:95 cases of chronic heart failure in our hospital were randomly divided into observation group (47 cases) and control group (48 cases). Control group patients were given basic treatment, and observation group received combination therapy of digoxin and Tongxinluo capsule, to detect and to investigate the changes of oxidative stress, cytokines and vascular endothelial function in two groups of patients before and after treatment.Results:There was no significant difference in oxidative stress, cytokines and vascular endothelial function between the two groups of chronic heart failure patients before treatment (P>0.05). Compared with before treatment, the malondialdehyde (MDA) and cytokines [tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin-6 (IL-6) and brain natriuretic peptide (BNP)] in two groups of patients with chronic heart failure after treatment decreased significantly (P<0.05), while indexes related to endothelial function [hyperemic brachial artery diameter after reactive hyperemia, brachial artery diameter change rate, brachial artery endothelial dependent diastolic function (FMD), and brachial artery endothelium dependent diastolic function (NMD)] and related indexes of oxidative stress [glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase (CAT)] were significantly increased (P<0.05). The related indexes and oxidative stress indexes (GSH-Px, CAT and SOD) of observation group after the combined treatment in patients with endothelial function were significantly higher than the control group after treatment (P<0.05). After treatment, cytokines and MDA levels were significantly lower than the control group (P<0.05).Conclusions:Tongxinluo capsule combined with digoxin treatment significantly improved the oxidative stress, cytokines and vascular endothelial function levels in patients with chronic heart failure, and has important clinical significance for the treatment of patients with chronic heart failure.

中医“肺肠合治”法联合双歧杆菌活菌胶囊在重症肺炎合并胃肠功能障碍患者中的应用效果

目的 分析中医“肺肠合治”法联合双歧杆菌活菌胶囊在重症肺炎合并胃肠功能障碍患者中的应用效果。方法 回顾性分析2019年6月至2023年6月该院重症监护室(ICU)收治的153例重症肺炎合并胃肠功能障碍患者的临床资料,根据不同治疗方案分为研究组(77例)和对照组(76例)。所有患者均接受基础治疗,对照组采用双歧杆菌活菌胶囊治疗,研究组在对照组基础上联合中医“肺肠合治”法治疗。比较两组基线资料、相关评分[急性生理学与慢性健康评价Ⅱ(APACHEⅡ)评分、序贯性脏器衰竭评价(SOFA)评分、胃肠功能衰竭(GIF)评分、临床肺部感染量表(CPIS)评分]、胃肠功能指标[胃泌素(GAS)、胃动素(MTL)、D-乳酸、二胺氧化酶(DAO)]、炎症指标[降钙素原(PCT)、C反应蛋白(CRP)]、病死率。结果 研究组ICU停留、机械通气时间明显短于对照组,治疗后两组氧合指数(PaO_(2)/FiO)均高于治疗前,且研究组均高于对照组,差异均有统计学意义(P<0.05)。治疗后两组APACHEⅡ评分、SOFA评分、GIF评分、CPIS评分及GAS、D-乳酸、DAO、PCT、CRP水平均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组MTL水平均高于治疗前,且研究组均高于对照组,差异均有统计学意义(P<0.05)。两组病死率比较,差异无统计学意义(P>0.05)。结论 在双歧杆菌活菌胶囊基础上联合中医“肺肠合治”法能有效缩短患者ICU停留、机械通气时间,改善PaO_(2)/FiO,恢复胃肠功能,降低炎症指标水平。

Efficacy and Safety of Zhuanggu Joint Capsules in Combination with Celecoxib in Knee Osteoarthritis： A Multi-center, Randomized, Double-blind, Double-dummy, and Parallel Controlled Trial

Background：Knee osteoarthritis （KOA） is a chronic joint disease that manifests as knee pain as well as different degrees of lower limb swelling,stiffness,and movement disorders.The therapeutic goal is to alleviate or eliminate pain,correct deformities,improve or restore joint functions,and improve the quality of life.This study aimed to evaluate the efficacy and safety of Zhuanggu joint capsules combined with celecoxib and the benefit of treatment with Zhuanggu alone for KOA.Methods：This multi-center,randomized,double-blind,double-dummy,parallel controlled trial,started from December 2011 to May 2014,was carried out in 6 cities,including Beijing,Shanghai,Chongqing,Changchun,Chengdu,and Nanjing.A total of 432 patients with KOA were divided into three groups （144 cases in each group）.The groups were treated,respectively,with Zhuanggu joint capsules combined with celecoxib capsule simulants,Zhuanggu joint capsules combined with celecoxib capsules,and celecoxib capsules combined with Zhuanggu joint capsule simulants for 4 weeks consecutively.The improvement of Western Ontario and McMaster Universities Osteoarthritis （WOMAC） index and the decreased rates in each dimension of WOMAC were evaluated before and after the treatment.Intergroup and intragroup comparisons of quantitative indices were performed.Statistically significant differences were evaluated with pairwise comparisons using Chi-square test （or Fisher＆#39;s exact test） and an inspection level ofα =0.0167.Results：Four weeks after treatment,the total efficacies of Zhuanggu group,combination group,and celecoxib group were 65%,80%,and 64%,respectively,with statistically significant differences among the three groups （P =0.005）.Intergroup pairwise comparisons showed that the total efficacy of the combination group was significantly higher than that of the Zhuanggu （P =0.005） and celecoxib （P =0.003）groups.The difference between the latter two groups was not statistically significant （P 〉 0.0167）.Four weeks after discontinuation,the efficacies of the three groups were 78%,95%,and 65%,respectively,with statistically significant differences （P 〈 0.0001）.Intergroup pairwise comparisons revealed that the efficacy of the combination group was significantly better than that of the Zhuanggu and the celecoxib groups （P 〈 0.0001）.The difference between the latter two groups was not statistically significant （P 〉 0.0167）.The incidences of adverse events in Zhuanggu group,combination group,and celecoxib group were 8.5%,8.5%,and 11.1%,respectively,with insignificant differences （P 〉 0.05）.Conclusions：Zhuanggu joint capsules alone or combined with celecoxib showed clinical efficacy in the treatment of KOA.The safety of Zhuanggu joint capsules alone or combined with celecoxib was acceptable.

Clinical Observation on the Treatment of Male Neoplastic Anemia with Yixuesheng Capsule(益血生胶囊) Combined with Recombination Human Erythropoietin

Objective:To explore the efficacy and mechanism of Yixuesheng capsule(益血生胶囊,YXS) combined with recombination human erythropoietin(RHE) in treating male neoplastic anemia(NA).Methods: Sixty-five patients were randomized into two groups,the 33 patients in the treated group treated with a combined therapy of YXS and RHE,and the 32 in the control group treated with RHE alone,all for 12 weeks.Related clinical indexes,including hemoglobin(Hgb),red blood cell(RBC),hematocrit(HMC),testosterone(T),estradiol (E_2) an...

通心络胶囊治疗脓毒症疗效及对微循环的影响

目的观察通心络胶囊对脓毒症患者临床疗效和微循环指标的影响。方法选取2018年11月—2021年10月河北以岭医院ICU收治的脓毒症患者60例,按照随机数字表法分为观察组和对照组,各30例。2组均给予西医常规治疗,观察组加用通心络胶囊,疗程均7 d。分别于入ICU 0、6、24、48、72 h检测大循环参数(MAP、CVP及ScvO_(2))、微循环参数(Pcv-aCO_(2)、Pcv-aCO_(2)/Ca-cvO_(2)、Lac、CRT)及APACHE-Ⅱ、SOFA评分、机械通气时间、ICU住院时间及28 d病死率。结果观察组临床疗效总有效率显著高于对照组(100.0%vs.66.7%,χ^(2)=8.857,P=0.003);2组0、6、24、48及72 h不同时间点大循环参数MAP、CVP及ScvO_(2)组内比较均具有统计意义(P均<0.001);而组间比较皆无统计意义(P均>0.05)。对照组0、6、24、48及72 h不同时间点Pcv-aCO_(2)组内比较差异具有统计学意义(P=0.006),Pcv-aCO_(2)/Ca-cvO_(2)组内比较无统计学意义(P=0.261);观察组Pcv-aCO_(2)及Pcv-aCO_(2)/Ca-cvO_(2)组内比较差异均具有统计学意义(P均<0.05);2组Pcv-aCO_(2)及Pcv-aCO_(2)/Ca-cvO_(2)在0、6、24 h组间比较差异均无统计学意义(P>0.05),但48及72 h组间比较均具有统计学意义(P均<0.05),观察组均优于对照组。2组0、6、24、48及72 h不同时间点Lac、CRT组内比较均具有统计学意义(P均<0.001);2组0、6、24、48 h Lac组间比较均无统计学意义(P均>0.05),72 h Lac组间比较差异具有统计学意义(P=0.036),观察组优于对照组;2组0、6、24 h CRT组间比较均无统计学意义(P均>0.05),48及72 h CRT组间比较差异均具有统计学意义(P均<0.05),观察组均优于对照组。2组7 d与1 d组内比较APACHE-Ⅱ及SOFA评分差异均有统计学意义(P均<0.001);2组APACHE-Ⅱ与SOFA评分1 d组间比较差异均无统计学意义(P均>0.05);7 d时APACHE-Ⅱ评分组间比较差异无统计学意义(P>0.05),SOFA评分组间比较差异有统计学意义(P=0.010),观察组优于对照组。2组在机械通气时间、ICU住院时间及28 d病死率方面比较差异均无统计学意义(P均>0.05)。结论通心络胶囊能够改善脓毒症患者微循环障碍,缓解病情,改善中医证候临床疗效,但未能缩短机械通气时间、ICU住院时间及28 d病死率。

腰硬联合麻醉复合髋关节囊周围神经阻滞在老年髋部骨折患者中的应用效果

目的分析老年髋部骨折患者联合腰硬复合麻醉、髋关节囊周围神经阻滞的作用。方法非随机选取2021年1月—2023年1月新疆生产建设兵团第十三师红星医院收治的120例老年髋部骨折患者为研究对象,均予以外科手术治疗,按照不同麻醉方式分为两组,各60例。对照组采取腰硬联合麻醉,观察组采取腰硬联合麻醉复合髋关节囊周围神经阻滞,比较两组患者应用效果。结果观察组术后中枢神经特异蛋白、β-淀粉样蛋白1-40水平分别为(94.28±13.23)mg/L、(6.52±0.94)mg/L,均较对照组的(130.54±23.89)mg/L、(9.81±1.55)mg/L低,差异有统计学意义(t=9.044、7.837,P均<0.05);观察组术后2、4、6、12 h的VAS评分较对照组低,差异有统计学意义(P均<0.05)。结论联合腰硬复合麻醉、髋关节囊周围神经阻滞用于老年髋部骨折患者,能够减轻患者术后疼痛,并降低术后中枢神经系统的损伤。

枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征效果和安全性的Meta分析

目的采用Meta分析方法评价枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征(IBS)的效果及安全性。方法系统检索了PubMed、Embase、中国生物医学文献、中国知网、万方、维普、Cochrane Library等数据库,检索时间截止至2023年6月。观察组采用枯草杆菌二联活菌肠溶胶囊单用或联合其他药物治疗,对照组采用其他药物单药或联合治疗。利用RevMan 5.4.1软件进行Meta分析。结果Meta分析结果显示,观察组总有效率优于对照组(相对危险度=1.20,P<0.001),腹痛、腹泻症状发生率均低于对照组(均P<0.05),而2组不良反应发生率差异无统计学意义(比值比=0.80,P=0.28)。亚组分析结果显示,观察组腹泻型IBS和便秘型IBS患者的治疗总有效率均高于对照组(均P<0.05)。结论基于目前的文献证据,枯草杆菌二联活菌肠溶胶囊治疗IBS有效性及安全性均较好。

胃复春胶囊结合二联疗法根除幽门螺杆菌的疗效观察

目的观察胃复春胶囊+二联疗法对根除H.pylori的疗效。方法选择2017年1月至2021年1月门诊接诊且首次H.pylori根除失败的150例H.pylori感染患者,随机分为3组:新四联疗法组(n=50)、二联疗法组(n=50)、胃复春胶囊+二联疗法组(n=50),评价组间炎症因子水平、症状积分、胃泌素17、复发率、H.pylori根除率。结果治疗14 d后,新四联疗法组、胃复春胶囊+二联疗法组炎症因子水平、症状积分、胃泌素17优于二联疗法组(P<0.05),但新四联疗法组与胃复春胶囊+二联疗法组在炎症因子水平、症状积分、胃泌素17方面差异无统计学意义(P>0.05);随访1个月,新四联疗法组、胃复春胶囊+二联疗法组复发率均低于二联疗法组(P<0.05),但新四联疗法组与胃复春胶囊+二联疗法组在复发率方面差异无统计学意义(P>0.05);三组于停药后28 d复查^(13)C呼气试验,结果显示新四联疗法组、胃复春胶囊+二联疗法组H.pylori根除率均高于二联疗法组(P<0.05),但新四联疗法组与胃复春胶囊+二联疗法组在H.pylori根除率方面差异无统计学意义(P>0.05)。结论胃复春胶囊+二联疗法对根除H.pylori有较好疗效,值得推广。

Clinical Observation on the Treatment of Chronic Urticaria with Total Glucosides of Paeony Capsule Combined with Citirizine

Objective： To assess the effect and adverse reaction of total glucosides of paeony capsule （TGPC） in combining with citirizine for the treatment of chronic urticaria. Methods： A total of 120 patients were assigned to two groups by lottery, 65 in the treated group and 55 in the control group. They all were orally treated with citirizine tablet 10 mg per day, but to the treated group, additional 0.2 g TGPC was given three times per day, the therapeutic course for both groups was 4 weeks. The effectiveness of treatment was observed, and the changes of total symptom score, serum levels of interleukin-4 （IL-4）, and immunoglobulin E （IgE） were measured before and after treatment. Moreover, a follow- up was carded out one month after ending the treatment. Results： The dropped cases were two in the treated group and seven in the control group; so, the study was accomplished on 63 patients in the treated group and 48 patients in the control group. The total effective rate was assessed at 73.02% （46/63） in the treated group, which was significantly higher than 47.92% （23/48） in the control group （P〈0.01）. After treatment, the total symptom score decreased in both groups, but the decrement in the treated group was more significant （P〈0.05）. Serum levels of IL-4 and IgE in the treated group lowered significantly, while the changes in the control group were insignificant, so statistical significant differences were shown between groups （P〈0.01）. A follow-up study showed that the relapse rate in the treated group was 30.00% （6/20）, while that in the control group was 90.00% （9/10）, and the former was lower than the latter （P〈0.01）. Adverse reactions, revealed as drowsiness, dizziness, and weakness, were seen in eight cases and seven cases in the two groups, respectively. Besides, mild diarrhea occurred in two cases of the treated group. Conclusions： The treatment of TGPC combining citirizine shows definite curative effect in treating chronic urticaria, with low relapse rate and without evident adverse reaction. Its therapeutic effect might be realized by means of regulating patients＇ immune function. Besides, the medication should be continued for a rather long peried to achieve the full effect.

双歧杆菌三联活菌胶囊及乳果糖联合哌拉西林/他唑巴坦治疗肝硬化合并自发性细菌性腹膜炎的临床效果

目的探讨双歧杆菌三联活菌胶囊及乳果糖联合哌拉西林/他唑巴坦治疗肝硬化合并自发性细菌性腹膜炎(SBP)的效果。方法选取2021年3月至2023年4月收治的88例肝硬化合并SBP患者,将其随机分为对照组(44例,哌拉西林/他唑巴坦治疗)及观察组(44例,双歧杆菌三联活菌胶囊及乳果糖联合哌拉西林/他唑巴坦治疗)。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。观察组的体温复常时间、腹部压痛消失时间、腹水常规检查正常时间及腹水消失时间短于对照组(P<0.05)。治疗1周后,观察组的肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平低于对照组,白细胞介素-10(IL-10)水平高于对照组(P<0.05)。治疗1周后,观察组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及自然杀伤(NK)细胞高于对照组(P<0.05)。治疗1周后,观察组的谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(GGT)及总胆红素(TBIL)水平明显低于对照组(P<0.05)。结论双歧杆菌三联活菌胶囊及乳果糖联合哌拉西林/他唑巴坦可改善肝硬化合并SBP患者的临床症状,降低机体炎症反应。

培菲康联合美沙拉嗪及康复新液治疗溃疡性结肠炎的效果研究

目的探讨双歧杆菌三联活菌胶囊(商品名:培菲康)联合美沙拉嗪及康复新液治疗溃疡性结肠炎的临床效果。方法89例接受药物治疗的溃疡性结肠炎患者,按随机数字表法分成对照组(40例)及研究组(49例)。对照组应用美沙拉嗪+康复新液治疗,研究组在对照组基础上联合应用培菲康治疗。对比两组治疗效果、症状消退时间、不良反应发生率、免疫功能指标(CD^(3+)、CD^(4+)/CD^(8+))水平、血清炎性因子指标[C反应蛋白(CRP)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)]水平、症状评分、生活质量评分。结果研究组总有效率97.96%高于对照组的82.50%(P<0.05)。研究组腹泻消退时间、腹痛消退时间、便血消退时间分别为(3.29±0.81)、(4.12±0.76)、(4.37±0.89)d,均短于对照组的(4.32±0.97)、(5.30±0.93)、(5.64±1.02)d(P<0.05)。两组不良反应发生率对比,差异不明显(P>0.05)。治疗后,两组CD^(3+)、CD^(4+)/CD^(8+)与治疗前相比均显著增高,且研究组CD^(3+)(45.39±2.87)%、CD^(4+)/CD^(8+)(2.10±0.48)均高于对照组的(41.18±2.91)%、(1.52±0.39)(P<0.05)。治疗后,两组CRP、PCT、TNF-α对比于治疗前均明显降低,且研究组CRP(5.89±1.06)mg/L、PCT(0.46±0.15)ng/ml、TNF-α(10.83±2.07)μg/L均低于对照组的(7.02±1.27)mg/L、(0.69±0.23)ng/ml、(13.49±2.46)μg/L(P<0.05)。治疗后,两组腹泻、腹痛、便血评分相比于治疗前均明显降低,且研究组腹泻、腹痛、便血评分分别为(1.17±0.39)、(1.06±0.31)、(1.16±0.40)分,均低于对照组的(1.58±0.43)、(1.52±0.48)、(1.61±0.45)分(P<0.05)。治疗后,两组生理、心理、环境、社会关系评分较治疗前均显著增高,且研究组生理、心理、环境、社会关系评分分别为(89.75±6.48)、(89.07±6.02)、(90.14±6.15)、(89.96±6.27)分,高于对照组的(82.93±6.85)、(82.40±6.13)、(83.27±6.30)、(83.14±6.54)分(P<0.05)。结论在溃疡性结肠炎患者治疗时,应用美沙拉嗪、康复新液与培菲康联合治疗可增强疗效,起到加快症状缓解、调节免疫功能、减轻炎症反应等作用,有助于改善生活质量,且联合用药后的不良反应未增多,具有良好的安全性。

双歧杆菌三联活菌胶囊联合匹维溴铵在肠易激综合征患者中的应用效果

目的:探究双歧杆菌三联活菌胶囊联合匹维溴铵在肠易激综合征患者中的应用效果及对肛肠动力学的影响。方法:选择2020年6月—2022年12月中国人民解放军海军第971医院收治的80例肠易激综合征患者,根据随机数字表法分为两组,每组40例。对照组采用匹维溴铵进行治疗,观察组则在对照组的基础上加用双歧杆菌三联活菌胶囊治疗。比较两组治疗总有效率、治疗前后的症状体征积分(腹痛、腹胀及大便性状)、肛肠动力学指标(肛管静息压、肛管收缩压及直肠最大容量)及生存质量[肠易激综合征-生存质量量表(IBS-QOL)]。结果:观察组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前两组症状体征积分、肛肠动力学指标及IBS-QOL评分比较,差异均无统计学意义(P>0.05);治疗后观察组症状体征积分、IBS-QOL评分均显著低于对照组,肛管静息压、肛管收缩压及直肠最大容量均显著高于对照组,差异均有统计学意义(P<0.05)。结论:双歧杆菌三联活菌胶囊联合匹维溴铵在肠易激综合征患者中的应用效果较好,可显著改善患者的肛肠动力学,减轻症状体征,提高生活质量。

枯草杆菌二联活菌胶囊联合含铋四联疗法治疗幽门螺旋杆菌感染的效果及对患者血清炎症因子的影响

目的探究枯草杆菌二联活菌胶囊联合含铋四联疗法治疗幽门螺旋杆菌(Hp)感染的效果及对患者血清炎性因子的影响。方法收集2022年1月1日至2023年7月31日苏州京东方医院消化内科收治的116例Hp感染者,根据随机数表法分为四联组(枸橼酸铋钾+阿莫西林+克拉霉素+奥美拉唑肠溶片)和活菌组(四联组基础上加服枯草杆菌二联活菌胶囊),每组58例。复查13C尿素呼气试验,比较2组治疗后Hp根除率。采用全自动生化分析仪检测患者血清炎症因子,采用Immage双光径浊度分析仪检测血清IgA、IgG水平,采用NanoFCM流式细胞仪检测血清CD3^(+)、CD4^(+)、CD8^(+)水平。结果治疗后,活菌组患者总有效率(96.55%)明显高于四联组(84.48%),差异有统计学意义(P<0.05)。治疗后,2组hs-CRP、IL-6、TNF-α、CD8+水平低于治疗前,IgA、IgG、CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)高于治疗前,差异有统计学意义(P<0.05)。治疗后,活菌组hs-CRP、IL-6、TNF-α、CD8+水平低于四联组,IgA、IgG、CD3^(+)、CD4^(+)水平及CD4^(+)/CD8+高于四联组,差异有统计学意义(P<0.05)。治疗后,活菌组Hp根除率(96.55%)显著高于四联组(79.31%),差异有统计学意义(P<0.05)。活菌组不良反应发生率显著低于四联组,差异有统计学意义(P<0.05)。结论枯草杆菌二联活菌胶囊联合含铋四联疗法治疗Hp感染疗效较好,能有效根除Hp,改善炎症因子指标,且安全性高。

奥美拉唑肠溶胶囊与地衣芽孢杆菌活菌胶囊联合治疗急性胃肠炎的效果评价

目的评价分析奥美拉唑肠溶胶囊联合地衣芽孢杆菌活菌胶囊治疗急性胃肠炎的临床效果。方法选取2023年1—6月本院收治的130例急性肠胃炎患者为研究对象,按照随机抽签分组方式将其划分为对照组(n=65)和观察组(n=65)。对照组只采用奥美拉唑肠溶胶囊进行治疗,观察组采用奥美拉唑肠溶胶囊联合地衣芽孢杆菌活菌胶囊用药方式进行治疗。对比分析两组治疗效果、症状改善时间、用药不良反应等情况。结果观察组临床效果优于对照组(P<0.05);观察组症状改善时间短于对照组(P<0.05);观察组用药不良反应总发生率小于对照组(P<0.05)。结论奥美拉唑肠溶胶囊与地衣芽孢杆菌活菌胶囊联合治疗急性肠胃炎具有显著的临床效果,能较好地改善患者腹痛、恶心、腹泻等临床症状,对患者机体损伤较轻。

双歧杆菌三联活菌胶囊联合阿托伐他汀钙、脂必泰治疗高脂血症患者的效果及对肠道菌群、内皮功能的影响

目的探讨双歧杆菌三联活菌胶囊联合阿托伐他汀钙、脂必泰治疗高脂血症患者的效果。方法选取2019年1月至2022年1月我院收治的100例高脂血症患者,以随机数字表法将其分为对照组和研究组,各50例。对照组给予阿托伐他汀钙联合脂必泰治疗,研究组在对照组基础上给予双歧杆菌三联活菌胶囊治疗。比较两组的治疗效果。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,研究组的双歧杆菌、乳酸杆菌数量多于对照组,大肠杆菌、粪肠球菌数量少于对照组(P<0.05)。治疗后,研究组的一氧化氮(NO)水平高于对照组,内皮素-1(ET-1)水平低于对照组(P<0.05)。治疗后,研究组的脂蛋白(a)[Lp(a)]、载脂蛋白B100(ApoB100)水平低于对照组,颈动脉内膜中层厚度(IMT)小于对照组(P<0.05)。研究组的不良反应总发生率低于对照组(P<0.05)。结论双歧杆菌三联活菌胶囊联合阿托伐他汀钙、脂必泰治疗高脂血症患者的效果显著,可调节肠道菌群,改善内皮功能、脂代谢紊乱及IMT。

培菲康联合美沙拉嗪与康复新液对溃疡性结肠炎患者炎症因子及不良反应的影响

目的探讨双歧杆菌三联活菌胶囊(商品名:培菲康)联合美沙拉嗪与康复新液对溃疡性结肠炎(UC)患者炎症因子及不良反应的影响。方法76例溃疡性结肠炎患者,以入院先后顺序分为对照组及观察组,每组38例。对照组以美沙拉嗪联合康复新液治疗,观察组在对照组基础上加入培菲康治疗。对比两组临床疗效、临床症状(大病次数、便血、腹泻、腹痛)评分、炎症因子[白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]水平及不良反应发生情况。结果观察组总有效率为92.11%,较对照组的73.68%更高,差异显著(P<0.05)。治疗后,观察组大便次数评分(0.75±0.23)分、便血评分(0.58±0.17)分、腹泻评分(0.53±0.16)分、腹痛评分(0.59±0.15)分均较对照组的(1.21±0.38)、(0.84±0.21)、(0.82±0.21)、(0.86±0.19)分更低,差异显著(P<0.05)。治疗后,观察组IL-8(140.64±32.83)μg/L、hs-CRP(3.06±0.86)mg/L、TNF-α(37.17±9.22)ng/L均较对照组的(172.14±39.14)μg/L、(4.45±0.94)mg/L、(48.55±9.53)ng/L更低,差异显著(P<0.05)。观察组不良反应发生率5.26%较对照组的21.05%更低,差异显著(P<0.05)。结论培菲康联合美沙拉嗪与康复新液治疗溃疡性结肠炎疗效确切,临床症状和体内炎症因子水平均可得到有效改善,且安全性较高。

双歧杆菌三联活菌胶囊治疗重症脑梗死营养不良患者的效果分析

目的:探讨双歧杆菌三联活菌胶囊治疗重症脑梗死营养不良患者的临床效果。方法:选取2019年12月—2022年12月兰陵县人民医院收治的68例重症脑梗死营养不良患者为研究对象,按随机数字表法将患者分为对照组与研究组,每组34例。对照组采用肠内营养支持治疗,研究组在对照组的基础上采用双歧杆菌三联活菌胶囊治疗。对比两组的营养状况分级、免疫功能及不良反应发生情况。结果:治疗后,研究组营养状况分级优于对照组,差异有统计学意义(P<0.05);两组外周T细胞亚群CD3^(+)、CD4^(+)、免疫球蛋白A、免疫球蛋白G、免疫球蛋白M水平均高于治疗前,且研究组均高于对照组,差异均有统计学意义(P<0.05)。研究组不良反应发生率为5.88%,低于对照组的23.53%,差异有统计学意义(P<0.05)。结论:双歧杆菌三联活菌胶囊可改善重症脑梗死营养不良患者的营养状况,提高其免疫功能,减少肠内营养支持治疗的不良反应,安全性高。

双歧杆菌三联活菌与多潘立酮联合艾灸治疗初诊脑梗死恢复期胃肠道功能紊乱临床评价

目的探讨双歧杆菌三联活菌、多潘立酮联合艾灸治疗初诊脑梗死恢复期患者胃肠道功能紊乱的临床效果。方法选取医院2021年8月至2024年4月收治的脑梗死恢复期并发胃肠道功能紊乱患者242例,按随机数字表法分为对照组和观察组,各121例。两组患者均予多潘立酮片及双歧杆菌三联活菌胶囊口服,观察组选择双侧足三里穴、肝腧穴、肾腧穴加予艾灸治疗,两组均持续治疗4周。结果观察组总有效率为96.69%,显著高于对照组的92.56%(P<0.05)。与对照组比较,观察组患者治疗后的双歧杆菌、乳杆菌显著增多,肠杆菌、肠球菌显著减少,胃泌素、胃动素、总蛋白、白蛋白水平显著升高,胃肠道症状分级量表各项目评分均显著降低(P<0.05)。结论双歧杆菌三联活菌、多潘立酮联合艾灸可改善初诊脑梗死恢复期胃肠道功能紊乱患者肠道菌群结构及胃肠道症状。